A harmful form of the tau protein, which builds up in Alzheimer's disease and similar brain disorders, can directly damage ...

Lilly's chief scientific officer Daniel Skovronsky revealed that orally active anti-tau drug LY3372689 – an O-GlcNAcase (OGA) inhibitor – failed a phase 2 study in early symptomatic Alzheimer's.

is a differentiated approach to targeting tau, with promising potential for patients.” BIIB080 is also being investigated in the randomized, double-blind, placebo-controlled phase 2 CELIA study ...

Last September, Roche/Genentech and AC Immune reported a comprehensive failure for their anti-tau antibody semorinemab at the interim stage of the phase 2 TAURIEL trial in patients with early ...